Gastrointestinal Infections Portfolio

Targeted molecular stool testing that decreases turnaround time, increases accuracy and aids in patient management

BD offers targeted syndromic panels to address clinical need and optimize results

Because it can be difficult to differentiate the cause of gastrointestinal illness, targeted testing allows clinicians to accurately decide which tests are needed according to the patient’s clinical presentation and history.

The BD MAX™ Enteric Panels provide rapid and improved detection (vs traditional methods) of bacterial, viral and parasite pathogens causing ≥ 95% of infectious diarrhoea. The comprehensive menu of enteric panels significantly reduces time, materials and labour on the stool bench within the Microbiology laboratory.

Patient management challenges

Infectious diarrhoea affects billions of people globally each year

  • ~1.7 billion cases of infectious gastroenteritis diarrhoea each year1
  • Infectious diarrhoea is the 2nd leading cause of the death in children under 5 years of age1
  • Norovirus resulted in a total of $4.2 billion in direct health system costs2

Diagnostic challenges

The limitations of traditional methods (including culture, microscopy and immunoassay) include:

  • Delayed results3
  • Difficulty growing certain organisms on culture media4
  • False negative results due to subjective interpretation of microscopy5
  • Poor sensitivity and limited detection of targets with immunoassays6

Targeted testing

Determining a specific clinical diagnosis can benefit a patient with infectious diarrhea by:

  • Directing appropriate therapy
  • Allowing the judicious use of antimicrobial agents
  • Improving patient satisfaction and life planning

Meet the BD MAX™ Enteric Suite assays

More timely and accurate results enable:

  • Optimal patient management and faster results reporting to inform clinical decisions
  • Improved clinical interventions, i.e. optimal antimicrobial usage and ability to bring in infection control measures earlier to prevent infection spread

BD’s focused syndromic approach provides the flexibility to optimize testing algorithms by selecting the most appropriate enteric panel(s) based on patient history/clinical presentation.

Enteric Bacterial Panel
  • Salmonella spp.
  • Campylobacter spp. (C. jejuni and C. coli)
  • Shigella spp. (including EIEC)
  • Shiga toxin 1/Shiga toxin 2 genes (found in STEC)
Extended Enteric Bacterial Panel
  • Plesiomonas shigelloides
  • Vibrio spp. (V. vulnuficus, V. parahaemo lyticus, V. cholerae)
  • Enterotoxigenic E. coli (ETEC)
  • Yersinia entercolitica
Enteric Parasite Panel
  • Giardia lamblia
  • Cryptosporidium (C. hominis and C. parvum)
  • Entamoeba histolytica
Enteric Viral Panel
  • Norovirus GI & GII
  • Rotavirus A
  • Adenovirus F40/41
  • Sapovirus (genogroups I, II, IV, V)
  • Human Astrovirus (hAstro)
Enteric Viral Panel-NR
  • Norovirus GI & GII
  • Rotavirus A

EIEC, Enteroinvasive Escherichia coli; ETEC, Enterotoxigenic Escherichia coli; hAstro, Human Astrovirus; STEC, Shiga toxin–producing Escherichia coli.

Shigella dysenteriae can possess a Shiga toxin gene identical to the Shiga toxin 1 found in STEC.

1. World Health Organization. Diarrhoeal disease. Available at: Accessed May 2020. 2. Bartsch et al. PLoS ONE. 2016;11(4):e0151219. 3. Mortensen et al. BMC Clin Pathol. 2015;15:9. 4. Anderson et al. J Clin Microbiol. 2014;52(4):1222-1224. 5. Centers for Disease Control and Prevention. Parasites – Amebiasis – Entamoeba histolytica Infection. Available at: Updated December 16, 2015. Accessed May 2020. 6. Humphries R et al. Clin Microbiol Rev. 2015;28(1):3-31.

Contact us

to discuss how we can support your enteric testing needs